Literature DB >> 23084023

Trisomy correction in Down syndrome induced pluripotent stem cells.

Li B Li1, Kai-Hsin Chang, Pei-Rong Wang, Roli K Hirata, Thalia Papayannopoulou, David W Russell.   

Abstract

Human trisomies can alter cellular phenotypes and produce congenital abnormalities such as Down syndrome (DS). Here we have generated induced pluripotent stem cells (iPSCs) from DS fibroblasts and introduced a TKNEO transgene into one copy of chromosome 21 by gene targeting. When selecting against TKNEO, spontaneous chromosome loss was the most common cause for survival, with a frequency of ~10(-4), while point mutations, epigenetic silencing, and TKNEO deletions occurred at lower frequencies in this unbiased comparison of inactivating mutations. Mitotic recombination events resulting in extended loss of heterozygosity were not observed in DS iPSCs. The derived, disomic cells proliferated faster and produced more endothelia in vivo than their otherwise isogenic trisomic counterparts, but in vitro hematopoietic differentiation was not consistently altered. Our study describes a targeted removal of a human trisomy, which could prove useful in both clinical and research applications.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23084023      PMCID: PMC3705773          DOI: 10.1016/j.stem.2012.08.004

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  26 in total

1.  Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells.

Authors:  Jonathan S Draper; Kath Smith; Paul Gokhale; Harry D Moore; Edna Maltby; Julie Johnson; Lorraine Meisner; Thomas P Zwaka; James A Thomson; Peter W Andrews
Journal:  Nat Biotechnol       Date:  2003-12-07       Impact factor: 54.908

2.  Identification and classification of chromosomal aberrations in human induced pluripotent stem cells.

Authors:  Yoav Mayshar; Uri Ben-David; Neta Lavon; Juan-Carlos Biancotti; Benjamin Yakir; Amander T Clark; Kathrin Plath; William E Lowry; Nissim Benvenisty
Journal:  Cell Stem Cell       Date:  2010-10-08       Impact factor: 24.633

3.  Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.

Authors:  Christian M Zwaan; Gertjan J L Kaspers; Rob Pieters; Karel Hählen; Gritta E Janka-Schaub; Christina H van Zantwijk; Dieuwke R Huismans; Esther de Vries; Marianne G Rots; Godefridus J Peters; Gerrit Jansen; Ursula Creutzig; Anjo J P Veerman
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

4.  Studies on Down's syndrome in tissue culture. I. Growth rates and protein contents of fibroblast cultures.

Authors:  D J Segal; E E McCoy
Journal:  J Cell Physiol       Date:  1974-02       Impact factor: 6.384

5.  The impaired transcription factor AP-1 DNA binding activity in lymphocytes derived from subjects with some symptoms of premature aging.

Authors:  E Sikora; E Radziszewska; T Kmieć; D Maślińska
Journal:  Acta Biochim Pol       Date:  1993       Impact factor: 2.149

6.  Increased low-level chromosome 21 mosaicism in older individuals with Down syndrome.

Authors:  E C Jenkins; N Schupf; M Genovese; L L Ye; D Kapell; B Canto; M Harris; D Devenny; J H Lee; W T Brown
Journal:  Am J Med Genet       Date:  1997-01-20

7.  Gene targeting in stem cells from individuals with osteogenesis imperfecta.

Authors:  Joel R Chamberlain; Ulrike Schwarze; Pei-Rong Wang; Roli K Hirata; Kurt D Hankenson; James M Pace; Robert A Underwood; Kit M Song; Michael Sussman; Peter H Byers; David W Russell
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

8.  Identification of aneuploidy-selective antiproliferation compounds.

Authors:  Yun-Chi Tang; Bret R Williams; Jake J Siegel; Angelika Amon
Journal:  Cell       Date:  2011-02-18       Impact factor: 41.582

9.  Identification of aneuploidy-tolerating mutations.

Authors:  Eduardo M Torres; Noah Dephoure; Amudha Panneerselvam; Cheryl M Tucker; Charles A Whittaker; Steven P Gygi; Maitreya J Dunham; Angelika Amon
Journal:  Cell       Date:  2010-09-16       Impact factor: 41.582

10.  Impairment of circulating endothelial progenitors in Down syndrome.

Authors:  Valerio Costa; Linda Sommese; Amelia Casamassimi; Roberta Colicchio; Claudia Angelini; Valentina Marchesano; Lara Milone; Bartolomeo Farzati; Alfonso Giovane; Carmela Fiorito; Monica Rienzo; Marco Picardi; Bice Avallone; Massimiliano Marco Corsi; Berardo Sarubbi; Raffaele Calabrò; Paola Salvatore; Alfredo Ciccodicola; Claudio Napoli
Journal:  BMC Med Genomics       Date:  2010-09-13       Impact factor: 3.063

View more
  66 in total

Review 1.  Non-embryo-destructive Extraction of Pluripotent Embryonic Stem Cells: Implications for Regenerative Medicine and Reproductive Medicine.

Authors:  R Dittrich; M W Beckmann; W Würfel
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-12       Impact factor: 2.915

Review 2.  Toward pluripotency by reprogramming: mechanisms and application.

Authors:  Tao Wang; Stephen T Warren; Peng Jin
Journal:  Protein Cell       Date:  2013-11       Impact factor: 14.870

3.  How to correct chromosomal trisomy.

Authors:  Christine M Disteche
Journal:  Cell Res       Date:  2013-10-01       Impact factor: 25.617

Review 4.  Down syndrome and the complexity of genome dosage imbalance.

Authors:  Stylianos E Antonarakis
Journal:  Nat Rev Genet       Date:  2016-12-28       Impact factor: 53.242

Review 5.  The Use of Induced Pluripotent Stem Cell Technology to Advance Autism Research and Treatment.

Authors:  Allan Acab; Alysson Renato Muotri
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 6.  A novel system for correcting large-scale chromosomal aberrations: ring chromosome correction via reprogramming into induced pluripotent stem cell (iPSC).

Authors:  Taehyun Kim; Kathleen Plona; Anthony Wynshaw-Boris
Journal:  Chromosoma       Date:  2016-11-23       Impact factor: 4.316

7.  HLA engineering of human pluripotent stem cells.

Authors:  Laura Riolobos; Roli K Hirata; Cameron J Turtle; Pei-Rong Wang; German G Gornalusse; Maja Zavajlevski; Stanley R Riddell; David W Russell
Journal:  Mol Ther       Date:  2013-04-30       Impact factor: 11.454

Review 8.  Modelling human disease with pluripotent stem cells.

Authors:  Richard Siller; Sebastian Greenhough; In-Hyun Park; Gareth J Sullivan
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

Review 9.  Genomic instability in pluripotent stem cells: implications for clinical applications.

Authors:  Suzanne E Peterson; Jeanne F Loring
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

Review 10.  Genome Editing in Human Pluripotent Stem Cells: Approaches, Pitfalls, and Solutions.

Authors:  William T Hendriks; Curtis R Warren; Chad A Cowan
Journal:  Cell Stem Cell       Date:  2016-01-07       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.